• Special Issue Topic

    Viral Hepatitis

    Submission Deadline: December 31, 2024

    Guest Editors

    Dr. Jinsheng Guo E-Mail

    Chief Physician of Medicine, Department of Gastroenterology and Hepatology, Zhong Shan Hospital, Department of Internal Medicine, Shanghai Medical College, Fudan University, Shanghai, China


    Prof. Youhua Xie E-Mail

    Professor, Key Laboratory of Medical Molecular Virology, Department of Microbiology and Parasitology, School of Basic Medical Sciences, Fudan University, Shanghai, China


    About the Special Issue

    Hepatitis B and C viral infections represent a significant global health concern, imposing substantial economic burdens. These infections have various clinical implications, such as acute and chronic hepatitis, liver cirrhosis, hepatic failure, and hepatocellular carcinoma (HCC). Among these, liver cirrhosis and HCC stand as the primary causes of mortality related to hepatitis virus-induced liver diseases. Consequently, identifying the risk factors for cirrhosis and HCC in patients with chronic HBV and HCV infection is of paramount importance.

    While effective antiviral treatment can inhibit HBV replication and reduce serum viral load, potentially alleviating liver damage and diminishing the development of cirrhosis and liver cancer, achieving a complete cure for hepatitis B and eliminating the risk of HBV-related cancer remains a challenging task. Additionally, Hepatitis B reactivation significantly impacts the management of comorbidities. On the other hand, for hepatitis C, the progress in direct-acting antiviral agents has been remarkable in achieving a cure. However, one potential barrier to this approach is the occurrence of resistance-associated substitutions.

    In this specific context of viral hepatitis, we aim to delve into the current progress and existing challenges surrounding the management of patients with viral hepatitis. Our ultimate goal is to work towards eradicating viral hepatitis, seeking more effective approaches to tackle these infections and improve patient outcomes.

    Keywords: hepatitis B virus, hepatitis C virus, chronic hepatitis, hepatic failure, liver cirrhosis, hepatocellular carcinoma, hepatitis B Reactivation, elimination of hepatitis virus

    Published Articles

    Open Access
    Review
    Hepatitis B virus: modes of transmission, immune pathogenesis, and research progress on therapeutic vaccines
    Hepatitis B virus (HBV) infection affects 262 million people worldwide, leading to over 820,000 deaths annually. The reason HBV has been a persistent issue for decades is that it is a non-cytopathic [...] Read more.
    Chunzheng Li ... Xianguang Yang
    Published: October 14, 2024 Explor Dig Dis. 2024;3:443–458
    DOI: https://doi.org/10.37349/edd.2024.00060
    View:33
    Download:2
    Times Cited: 0
    Open Access
    Review
    The impact of hepatitis B virus (HBV) splicing on HBV replication and disease progression
    Chronic hepatitis B (CHB) disease caused by persistent infection with hepatitis B virus (HBV) is a global health problem affecting almost 300 million people worldwide, resulting in up to 1 million d [...] Read more.
    Laura C. McCoullough ... Peter A. Revill
    Published: August 07, 2024 Explor Dig Dis. 2024;3:326–343
    DOI: https://doi.org/10.37349/edd.2024.00054
    View:412
    Download:20
    Times Cited: 0
    Open Access
    Review
    Key points for the management of hepatitis C in the era of pan-genotypic direct-acting antiviral therapy
    Hepatitis C viral infections present a significant global health challenge, carrying substantial economic implications. These infections manifest in various clinical forms, including acute and chron [...] Read more.
    Hao Xiong, Jinsheng Guo
    Published: June 18, 2024 Explor Dig Dis. 2024;3:226–240
    DOI: https://doi.org/10.37349/edd.2024.00049
    View:637
    Download:21
    Times Cited: 0